PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million
Reuters2026/08/05 20:52- Pacific Biosciences posted Q2 2026 revenue of USD 39 million, down 2% year over year; consumables rose 6% to USD 20.1 million.
- GAAP net loss widened to USD 44.7 million while GAAP net loss per share held at USD 0.14.
- GAAP gross margin fell 5 percentage points to 32% due to higher compute and memory costs, Vega manufacturing transition costs, lower Revio average selling prices.
- Revio system placements climbed to 20, Vega placements slipped to 26; annualized Revio pull-through per system eased to about USD 202,000.
- Forecast 2026 revenue of USD 155 million to USD 165 million; began global SPRQ-Nx rollout, listing whole-genome sequencing at USD 345 per genome.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
IX Biopharma seeks SGX-ST trading halt lift for shares in Singapore
Crypto prices
More
